Article Text

Download PDFPDF
Bronchoscopic intratumoral injections of cisplatin and endostar as concomitants of standard chemotherapy to treat malignant central airway obstruction
  1. Wenqing Jiang1,
  2. Xiaoping Yang1,
  3. Xuekun Wang2,
  4. Yue Li1,
  5. Xinai Yang1,
  6. Na Wang1,
  7. Bin Yin1
  1. 1 Department of Respiratory Diseases, Qingdao Haici Hospital, Qingdao, China
  2. 2 Department of Respiration, Qingdao Central Hospital, Qingdao, China
  1. Correspondence to Bin Yin, Department of Respiratory Diseases, Qingdao Haici Hospital, Qingdao, China;qd0532yb{at}163.com

Abstract

Study Purpose Malignant central airway obstruction (CAO) in non-small cell lung cancer (NSCLC) is associated with high morbidity and requires endobronchial palliative treatment to re-establish a free air passage. We investigate intratumoral therapy combining anti-angiogenic and cytotoxic as a feasible therapeutic modality to treat malignant CAO.

Study Design Ten NSCLC subjects with symptomatic malignant CAO underwent endobronchial intratumoral cisplatin and Endostar co-injection after tumour debulking next to systemic cisplatin-based chemotherapy. Injection was performed immediately after debulking surgery and was then carried out on day 2, day 6 and day 10 past systemic chemotherapy. Nine subjects of control group constantly received traditional cisplatin-based chemotherapy. Bronchoscopy, CT scanning, histology, FEV1/FVC ratio, Karnofsky performance (KPS) and shortness of breath scores were analysed to assess therapeutic efficacy.

Results All 10 subjects benefited from the intratumoral cisplatin and endostar co-injection and systemic chemotherapy combination therapy. Bronchoscopy and CT scanning analyses showed a massive airway widening after treatment. Increased KPS and reduced shortness of breath score were also observed. A substantial improvement of lung function was further confirmed by increased FEV1/FVC ratio. For subjects of control group, the improvement was moderate and obviously not as optimal as the 10 subjects with intratumoral injection.

Conclusions We have shown that the intratumoral injection of cytotoxic cisplatin plus anti-angiogenic Endostar is an effective and safe adjuvant therapeutic option to treat malignant CAO in clinical practice. This time-staggered local and systemic treatment combination improves quality of life and clinical parameters, thus may provide a feasible therapeutic option for symptomatic CAO.

  • General medicine (see Internal Medicine)

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Wenqing Jiang and Xiaoping Yang as the co-first author.

  • Abbreviations NSCLC, Non-small cell lung cancer; CAO, Central airway obstruction; EITC, endobronchial intratumoral chemotherapy; KPS, Karnofsky Performance Status.

  • Contributors WJ, XY, XW, YL, XY and NW: Methodology, writing-original draft. BY: Conceptualisation, Supervision, writing-original draft and writing-review & editing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval Informed written consent was obtained from all participants and the present study was approved by the Qingdao Haici Hospital (2016HC06LQ036).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article.